SecBot SecBot
6-K ·Filed May 5, 2026

BNTX

BioNTech SE
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001776985-26-000031
Notable filing: 6-K
Actionable Insight ▼ Bearish

The Q1 results confirm accelerating COVID-19 revenue erosion and deepening operating losses as the company invests heavily in oncology pipeline. The $1.0B buyback provides a floor but does not offset fundamental deterioration. The manufacturing consolidation signals management's recognition of overcapacity but carries execution risk and upfront costs. Key catalysts to watch: Phase 2 pumitamig data at ASCO (May 29-June 2), trastuzumab pamirtecan BLA filing timeline, and interim data from multiple late-stage trials expected through 2026.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$95.50
T+0 close · May 5, 2026 · via day close
Latest settled
−2.77%
T+60 · $92.85
Vs SPY
−5.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $95.50entry
  2. T+1 · 7mo ago −0.25%α −1.64% · $95.26
  3. T+5 · 6mo ago −1.93%α −3.91% · $93.66
  4. T+20 · 6mo ago −6.66%α −11.61% · $89.14
  5. T+60 · 4mo ago −2.77%α −5.51% · $92.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech reported Q1 2026 results with total revenue of €118.1M, down 35% YoY from €182.8M, driven by a 50% decline in COVID-19 vaccine revenue to €66.9M. Net loss widened to €531.9M (€2.10 per share) from €415.8M (€1.73 per share) in Q1 2025, as R&D spending increased 6% to €557.0M and operating loss grew to €677.5M. Post-period, the company announced a $1.0B ADS repurchase program and a major manufacturing footprint consolidation affecting up to ~2,000 positions across multiple sites.

Key Facts

  • Q1 2026 total revenue €118.1M, down 35% YoY from €182.8M
  • COVID-19 vaccine revenue fell 50% YoY to €66.9M
  • Net loss widened to €531.9M (€2.10/share) from €415.8M (€1.73/share)
  • Operating loss increased to €677.5M from €534.1M
  • R&D expenses rose 6% to €557.0M; sales & marketing up 104% to €27.9M
  • Cash & investments totaled €16.76B as of March 31, 2026
  • Post-period: $1.0B ADS repurchase program authorized
  • Post-period: Manufacturing consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites affecting ~1,860 positions; JPT exit affecting ~140 positions
  • Impairment of €29.9M on BNT331 program (paused)
  • Pipeline prioritization costs of €18.7M in Q1

Financial Impact

Revenue decline of €64.7M (35% YoY); net loss increase of €116.1M (28% YoY); operating loss increase of €143.4M (27% YoY)

revenuenet lossoperating lossR&D expensesSG&A expenses

Risk Factors

  • Continued COVID-19 revenue decline with no near-term replacement revenue stream
  • Manufacturing consolidation execution risk and potential cash costs
  • Multiple ongoing patent litigations (Moderna, GSK, Arbutus, Bayer) with uncertain outcomes
  • Heavy R&D spend may not yield approved products for years
  • Pipeline prioritization may lead to further program discontinuations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000031
Document: form6-kq12026quarterlyrepo.htm0001776985-26-000031
Document: 0001776985-26-000031-index-headers.html0001776985-26-000031
Document: 0001776985-26-000031-index.html0001776985-26-000031
Document: 0001776985-26-000031.txt0001776985-26-000031

Track record

38 reports on BNTX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026